When did jardiance go generic?

When did Jardiance (empagliflozin) go generic?

Jardiance went off patent and entered a generic phase in the U.S. in August 2022, when the first generic empagliflozin products were approved and launched around that time [1].

What approval date matters vs. “went generic” in the market?

Generic manufacturers typically need an FDA approval (often an Abbreviated New Drug Application, or ANDA) before products appear in pharmacies. For Jardiance, the “went generic” timing is commonly tracked from the period when FDA-approved generics began reaching the market in 2022 [1].

What about brand exclusivity—did it end later?

Brand protection and exclusivity can extend beyond the initial patent expiration, which is why you can see a gap between patent-expiration timing and when generics are actually sold. For empagliflozin/Jardiance, the generic availability timing that patients and pharmacies experienced lined up with FDA-approved generics rolling out in 2022 [1].

Sources

[1] https://www.drugpatentwatch.com/p/jardiance (DrugPatentWatch.com, Jardiance/empagliflozin patent and generic-entry timeline)